Lobo Cynthia Lizzie, M Manohar, Shetty Amitha, S Ananya, K Pallavi, Dubey Akhilesh
Nitte (Deemed to be University), NGSM Institute of Pharmaceutical Sciences, Department of Pharmaceutics, Mangaluru, India.
Heliyon. 2024 Feb 20;10(4):e25598. doi: 10.1016/j.heliyon.2024.e25598. eCollection 2024 Feb 29.
Breast cancer treatment options are diverse, with tamoxifen commonly used as a selective estrogen receptor modulator (SERM) for hormone receptor-positive breast cancer. However, tamoxifen can have adverse systemic effects. Local transdermal therapy offers a potential solution by delivering the drug directly to the breast and minimizing systemic exposure. Hesperidin, a flavonoid, exerts synergistic effects when combined with anticancer agents. This combination therapy may be a more effective approach to breast cancer management. Analytical methods have been developed to quantify 4-Hydroxytamoxifen (4-HT) and hesperidin separately; however, no method currently exists for their simultaneous quantification in pharmaceutical formulations. This study aimed to develop and validate a reverse-phase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantification of 4-HT and hesperidin in liposomal formulations. A Design of Experiments (DoE) approach was employed using a Box-Behnken design (BBD) to optimize the RP-HPLC method. BBD allowed for a reduction in the number of required tests by creating a statistical model to estimate the significance of various factors and interactions. The methanol concentration, flow rate, and injection volume were considered as independent variables for optimization. A mobile phase (90:10 ratio of methanol: 0.1% v/v orthophosphoric acid) with a flow rate of 0.4 mL/min, and an injection volume of 10 μL was selected as optimized chromatographic condition. 4-HT showed a retention time (Rt) of 5.05 min and hesperidin showed an Rt of 7.11 min using an optimized analytical method and was detected at 275 nm. The developed RP-HPLC method was validated according to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, confirming its accuracy, precision, linearity, selectivity, and robustness. The validated method was then successfully applied to determine the entrapment efficiency and permeation of 4-HT and hesperidin into loaded liposomes. This study fills a gap in the literature by providing a simple and reliable RP-HPLC method for the simultaneous quantification of 4-HT and hesperidin in liposomal formulations.
乳腺癌的治疗选择多种多样,他莫昔芬通常作为一种选择性雌激素受体调节剂(SERM)用于激素受体阳性乳腺癌的治疗。然而,他莫昔芬可能会产生不良的全身影响。局部透皮疗法通过将药物直接输送到乳房并减少全身暴露,提供了一种潜在的解决方案。橙皮苷是一种类黄酮,与抗癌药物联合使用时具有协同作用。这种联合疗法可能是一种更有效的乳腺癌治疗方法。已经开发出分析方法来分别定量4-羟基他莫昔芬(4-HT)和橙皮苷;然而,目前尚无在药物制剂中同时定量它们的方法。本研究旨在开发并验证一种反相高效液相色谱(RP-HPLC)方法,用于同时定量脂质体制剂中的4-HT和橙皮苷。采用实验设计(DoE)方法,使用Box-Behnken设计(BBD)来优化RP-HPLC方法。BBD通过创建一个统计模型来估计各种因素和相互作用的显著性,从而减少了所需测试的数量。将甲醇浓度、流速和进样体积作为优化的自变量。选择流速为0.4 mL/min、进样体积为10 μL的流动相(甲醇与0.1% v/v正磷酸的比例为90:10)作为优化的色谱条件。使用优化的分析方法,4-HT的保留时间(Rt)为5.05分钟,橙皮苷的Rt为7.11分钟,并在275 nm处检测。根据人用药品注册技术要求国际协调会议(ICH)指南对所开发的RP-HPLC方法进行了验证,证实了其准确性、精密度、线性、选择性和稳健性。然后将经过验证的方法成功应用于测定4-HT和橙皮苷在负载脂质体中的包封效率和渗透率。本研究通过提供一种简单可靠的RP-HPLC方法,用于同时定量脂质体制剂中的4-HT和橙皮苷,填补了文献中的空白。